Guidance for Industry and Investigators on Enforcement of Safety Reporting Requirements for Investigational New Drug Applications and Bioavailability/Bioequivalence Studies; Availability
Health and Human Services Department; Food and Drug Administration · 2011
Read Guidance for Industry and Investigators on Enforcement of Safety Reporting Requirements for Investigational New Drug Applications and Bioavailability/Bioequivalence Studies; Availability by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-13950.txt.
Description
Rule published in the Federal Register on 2011-06-07 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 32863-32864] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-13950] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 312 and 320 [Docket No. FDA-2010-D-0482] Guidance for Industry and Investigators on Enforcement of Safety Reporting.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Guidance for Industry and Investigators on Enforcement of Safety Reporting Requirements for Investigational New Drug Applications and Bioavailability/Bioequivalence Studies; Availability
Citation: us:fr:2011-13950
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/06/07/2011-13950/guidance-for-industry-and-investigators-on-enforcement-of-safety-reporting-requirements-for
Context: Rule published in the Federal Register on 2011-06-07 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).
[Pages 32863-32864]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-13950]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 312 and 320
[Docket No. FDA-2010-D-0482]
Guidance for Industry and Investigators on Enforcement of Safety
Reporting Requirements for Investigational New Drug Applications and
Bioavailability/Bioequivalence Studies; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notification of guidance.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry and investigators entitled
``Enforcement of Safety Reporting Requirements for INDs and BA/BE
Studies.'' This guidance is intended to inform sponsors and
investigators of FDA's intent to exercise enforcement discretion
regarding the reporting requirements in the final rule,
``Investigational New Drug Safety Reporting Requirements for Human Drug
and Biological Products and Safety Reporting Requirements for
Bioavailability and Bioequivalence Studies in Humans'' (75 FR 59935,
September 29, 2010), until September 28, 2011. This action is being
taken in response to requests from sponsors to extend the March 28,
2011, effective date of the final rule. FDA expects all sponsors and
investigators to be in compliance with the new regulations no later
than September 28, 2011.
DATES: Submit either electronic or written comments on Agency guidances
at any time.
ADDRESSES: Submit written requests for single copies of the guidance to
the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, rm. 2201, Silver Spring, MD 20993-0002; or the Office of
Communication, Outreach and Development (HFM-40), Center for Biologics
Evaluation and Research, Food and Drug Administration, 1401 Rockville
Pike, suite 200N, Rockville, MD 20852-1448. Send one self-addressed
adhesive label to assist that office in processing your requests. See
the SUPPLEMENTARY INFORMATION section for electronic access to the
guidance document.
Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-
[[Page 32864]]
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Stephanie Shapley, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6323, Silver Spring, MD 20993-0002, 301-
796-4836; or Laura Rich, Center for Biologics Evaluation and Research
(HFM-17), Food and Drug Administration, 1401 Rockville Pike, suite
200N, Rockville, MD 20852-1448, 301-827-6210.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a guidance for industry and
investigators entitled ``Enforcement of Safety Reporting Requirements
for INDs and BA/BE Studies.'' This guidance is being issued consistent
with FDA's good guidance practices (GGPs) regulation (Sec. 10.115 (21
CFR 10.115)). The guidance provides that the Agency intends to grant a
6-month period of enforcement discretion relating to the new reporting
requirements (described in this document) that became effective on
March 28, 2011. Accordingly, this guidance is being implemented without
prior public comment because the Agency has determined that prior
public participation is not feasible or appropriate (Sec.
10.115(g)(2)). The Agency made this determination because the guidance
deals with a short-term and highly time-sensitive issue. Although this
guidance document is immediately in effect, it remains subject to
comment in accordance with the Agency's GGPs regulation.
On September 29, 2010, FDA published a final rule ``Investigational
New Drug Safety Reporting Requirements for Human Drug and Biological
Products and Safety Reporting Requirements for Bioavailability and
Bioequivalence Studies in Humans'' (75 FR 59935) and issued related
draft guidance ``Safety Reporting Requirements for INDs and BA/BE
Studies'' (75 FR 60129, Docket No. FDA-2010-D-0482). The final rule
amended the investigational new drug safety reporting requirements
under part 312 (21 CFR part 312) and added safety reporting
requirements for persons conducting bioavailability and bioequivalence
studies under part 320 (21 CFR part 320). The effective date for the
final rule was March 28, 2011. In comments to the docket, and in other
communications to the Agency placed in the docket, stakeholders have
requested an extension to the effective date of the final rule because
of the need for significant internal process changes in order to meet
the new requirements. Specifically, the comments indicated that
sponsors needed additional time to implement changes to their internal
procedures to comply with the new reporting requirements. The Agency
acknowledges these concerns and intends to exercise enforcement
discretion regarding the reporting requirements in the final rule until
September 28, 2011. During this period of time, FDA does not intend to
take enforcement action if sponsors and investigators report in
compliance with the reporting requirements under Sec. Sec. 312.32,
312.64, and 320.31 that were in effect prior to March 28, 2011.
The guidance represents the Agency's current thinking on
enforcement of safety reporting requirements for investigational new
drug applications and bioavailability/bioequivalence studies. It does
not create or confer any rights for or on any person and does not
operate to bind FDA or the public. An alternative approach may be used
if such approach satisfies the requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm, or http://www.regulations.gov. Always access an FDA guidance document by using
FDA's Web site listed previously to find the most current version of
the guidance.
Dated: June 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-13950 Filed 6-6-11; 8:45 am]